President
PharmaCadence
Hatfield, Pennsylvania
Dr. Fernández-Metzler joined the Department of Drug Metabolism at Merck & Co, Inc. in 1992 where she was a group leader, scientific mentor, and project team representative in the Preclinical Drug Metabolism group over the course of more than 18 years. During this time, Dr. Fernández-Metzler was responsible for developing and applying mass spectrometric and ligand binding analytical approaches to support discovery and development of small molecule and biologics drug candidates. As team leader, she collaborated in the design and implementation of departmental and cross-functional analytical strategies for the support of large molecule therapeutic modalities, including antibodies, proteins, peptides and siRNA. Under Dr. Fernández-Metzler’s guidance analytical techniques including, mouse microsampling, miniaturization of ELISA, and universal immunoassay formats were integrated into routine discovery PK of biologics. In addition, LC-MS/MS approaches for the quantitative analysis of proteins, PEGylated proteins and peptides in biological matrices were developed to support early discovery PK studies.
In the Fall of 2010, Dr. Fernández-Metzler was named President of PharmaCadence Analytical Services, LLC, an analytical research contract organization located in Hatfield, Pennsylvania.
Dr. Fernández-Metzler graduated from the Massachusetts Institute of Technology with a S.B. in Chemistry. She obtrained her Ph.D. in Chemistry from the University of Pennsylvania.
Disclosure information not submitted.
Tuesday, October 22, 2024
3:45 PM – 4:00 PM MT